CD19 and neoplasm: To directly study the physiology described above in tumor immunotherapy, we next generated human anti-CD19 chimeric antigen receptor (CAR) T cells in IL-2, IL-15, or OMCPmutIL-2 and noted improved lysis of human tumors in vitro (Figure 9A).